Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 October 2013Website:
http://www.admabiologics.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 96 min agoDividend
Analysts recommendations
Institutional Ownership
ADMA Latest News
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Adma Biologics (ADMA) concluded the recent trading session at $16.71, signifying a +1.7% move from its prior day's close.
RAMSEY, N.J. and BOCA RATON, Fla.
NEW YORK--(BUSINESS WIRE)---- $ADMA #ADMA--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independ.
NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.
What type of business is ADMA Biologics?
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
What sector is ADMA Biologics in?
ADMA Biologics is in the Healthcare sector
What industry is ADMA Biologics in?
ADMA Biologics is in the Biotechnology industry
What country is ADMA Biologics from?
ADMA Biologics is headquartered in United States
When did ADMA Biologics go public?
ADMA Biologics initial public offering (IPO) was on 17 October 2013
What is ADMA Biologics website?
https://www.admabiologics.com
Is ADMA Biologics in the S&P 500?
No, ADMA Biologics is not included in the S&P 500 index
Is ADMA Biologics in the NASDAQ 100?
No, ADMA Biologics is not included in the NASDAQ 100 index
Is ADMA Biologics in the Dow Jones?
No, ADMA Biologics is not included in the Dow Jones index
When was ADMA Biologics the previous earnings report?
No data
When does ADMA Biologics earnings report?
The next expected earnings date for ADMA Biologics is 08 November 2024